1
|
Schäfer J, Graubner C, Gerber V, Drögemüller C, Underberg J, Gurtner C, Unger L. [Ocular and non-ocular squamous cell carcinomas in the Haflinger: Eight cases at the Institut Suisse de Médecine Equine (2015-2022)]. SCHWEIZ ARCH TIERH 2023; 165:644-655. [PMID: 37822247 DOI: doi.org/10.17236/sat00406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/13/2023]
Abstract
INTRODUCTION This case series describes the clinical course of ocular and non-ocular squamous cell carinoma (SCC) in the Haflinger horse and is intended to raise awareness of the high recurrence rate and tendency to metastasize. Eight Haflingers with histologically confirmed SCC were included, five ocular and three non-ocular, who were presented at the Institut Suisse de Médecine Équine (ISME) Bern between July 2015 and January 2022. The ocular SCC cases were all presented because of an apparent mass, which in most cases was post-treatment recurrence. The occurrence of recurrences was observed between 3 weeks and 16 years after initial therapy. Four of five Haflingers with ocular SCC had an enucleation, three of which were clinically normal at the time of the completion of this study, one case was euthanized due to confirmed metastases and one due to lameness. The result of enucleations for therapy of ocular SCC was good if no metastases occurred. Of the three non-ocular SCC cases, only one case, a penile SCC, had an apparent mass. Therapy was initiated in this case, while the other two cases were euthanized shortly after diagnosis due to the poor prognosis of SCC in the appropriate locations (maxillary sinus, mandible). Metastases occurred three and two years after removal of the primary tumor in ocular SCC in the scapula, liver and lungs and in non-ocular SCC from the penis to the nostrils. Since a postmortem pathological examination was not carried out on all Haflingers, further metastases cannot be ruled out. Haflingers with SCC should be monitored by a veterinarian over the long term, as recurrences and/or metastases can still occur years later.
Collapse
Affiliation(s)
- J Schäfer
- Institut Suisse de Médecine Equine (ISME), Departement für klinische Veterinärmedizin, Vetsuisse-Fakultät, Universität Bern
| | - C Graubner
- Institut Suisse de Médecine Equine (ISME), Departement für klinische Veterinärmedizin, Vetsuisse-Fakultät, Universität Bern
| | - V Gerber
- Institut Suisse de Médecine Equine (ISME), Departement für klinische Veterinärmedizin, Vetsuisse-Fakultät, Universität Bern
| | - C Drögemüller
- Institut für Genetik, Vetsuisse-Fakultät, Universität Bern
| | - J Underberg
- Klinische Radiologie, Departement für klinische Veterinärmedizin, Vetsuisse-Fakultät, Universität Bern
| | - C Gurtner
- Institut für Tierpathologie, Vetsuisse-Fakultät, Universität Bern
| | - L Unger
- Institut Suisse de Médecine Equine (ISME), Departement für klinische Veterinärmedizin, Vetsuisse-Fakultät, Universität Bern
| |
Collapse
|
2
|
Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med 2022; 134:752-762. [PMID: 36004573 DOI: 10.1080/00325481.2022.2117498] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States. Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal risk factor for ASCVD. Current evidence overwhelmingly demonstrates that lowering LDL-C reduces the risk of secondary cardiovascular events in patients with previous myocardial infarction or stroke. There is no lower limit for LDL-C: large, randomized studies and meta-analyses have found continuous benefit and no safety concerns in patients achieving LDL-C levels <25 mg/dL. As 'Time is plaque' in patients with ASCVD, early, sustained reductions in LDL-C are critical to slow or halt disease progression. However, despite use of lipid-lowering medications, <30% of patients with ASCVD achieve guideline-recommended reductions in LDL-C, resulting in a substantial societal burden of preventable cardiovascular events and early mortality. LDL-C goals are not met due to several factors: lipid-lowering therapy is not initiated and intensified as directed by clinical guidelines (clinical inertia); most patients do not adhere to prescribed medications; and high-risk patients are frequently denied access to add-on therapies by their insurance providers. Promoting patient and clinician education, multidisciplinary collaboration, and other interventions may help to overcome these barriers. Ultimately, achieving population-level guideline-recommended reductions in LDL-C will require a collaborative effort from patients, clinicians, relevant professional societies, drug manufacturers, and payers.
Collapse
Affiliation(s)
| | - Peter P Toth
- Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Fatima Rodriguez
- Division of Cardiovascular Medicine and the Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
3
|
Maki KC, Bays H, Ballantyne C, Underberg J, Kastelein J, Johnson J, Ferguson J. An Open-label, Crossover Study Comparing EPA+DPA-Free Fatty Acids and EPA-Ethyl Esters in Adults with Elevated Triglycerides: ENHANCE-IT. J Clin Lipidol 2022. [DOI: 10.1016/j.jacl.2021.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
4
|
Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, CerezoOlmos C, Underberg J, Keech A, Tokgözoğlu L, Bonaca MP. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis 2021; 319:51-61. [PMID: 33476944 DOI: 10.1016/j.atherosclerosis.2020.12.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2020] [Revised: 12/01/2020] [Accepted: 12/16/2020] [Indexed: 12/24/2022]
Abstract
Elevated low-density lipoprotein cholesterol (LDL-C) is a principally modifiable cause of atherosclerotic cardiovascular disease; accordingly, recent European and US multisociety dyslipidaemia guidelines emphasise the importance of lowering LDL-C to reduce cardiovascular risk. This review provides perspectives on established and emerging agents that reduce LDL-C to help providers synthesize the abundance of new evidence related to prevention of cardiovascular disease. We provide hypothetical cases of patients with different cardiovascular risk factors and medical histories to illustrate application of current lipid-lowering guidelines in various clinical settings. As a core focus of preventive therapy, both European and US lipid management guidelines emphasise the importance of identifying patients at very high cardiovascular risk and treating to achieve LDL-C levels as low as possible, with European guidelines setting a goal of <1.4 mmol/L (<55 mg/dL) in patients with very high-risk cardiovascular disease. The proprotein convertase subtilisin/kexin type 9 inhibitors are now included in the guidelines and may fulfil an important unmet need for very high-risk patients who are not able to achieve LDL-C goals with conventional agents. The recently approved bempedoic acid and other promising agents under development will add to the armamentarium of lipid-lowering drugs available for clinicians to help patients meet their treatment goals.
Collapse
Affiliation(s)
- Dan Atar
- Department of Cardiology, Oslo University Hospital Ullevål, University of Oslo, Oslo, Norway.
| | - J Wouter Jukema
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| | | | - Pam R Taub
- Division of Cardiovascular Medicine, University of California San Diego, San Diego, CA, USA
| | - Shinya Goto
- Tokai University School of Medicine, Metabolic Disease Research Center, Tokai University Graduate School of Medicine, and Keio University School of Medicine, Kanagawa, Japan
| | - François Mach
- Department of Cardiology, Geneva University Hospitals, Geneva, Switzerland
| | | | - James Underberg
- New York University Langone Medical Center, New York, NY, USA
| | - Anthony Keech
- Central Clinical School, Sydney Medical School, University of Sydney and Royal Prince Alfred Hospital, Camperdown, NSW, Australia
| | - Lale Tokgözoğlu
- Department of Cardiology, Hacettepe University, Ankara, Turkey
| | - Marc P Bonaca
- UCHealth University of Colorado Hospital, Aurora, CO, USA
| |
Collapse
|
5
|
De Jesus S, Underberg J, Gordon B, Hudgins L, Nahrwold R, Gianos E. An Approach to PCSK9-inhibitor Non-Responders- A Case Series. J Clin Lipidol 2020. [DOI: 10.1016/j.jacl.2020.05.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Garshick MS, Baumer Y, Dey AK, Grattan R, Ng Q, Teague HL, Yu ZX, Chen MY, Tawil M, Barrett TJ, Underberg J, Fisher EA, Krueger J, Powell-Wiley TM, Playford MP, Berger JS, Mehta NN. Characterization of PCSK9 in the Blood and Skin of Psoriasis. J Invest Dermatol 2020; 141:308-315. [PMID: 32615123 DOI: 10.1016/j.jid.2020.05.115] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2020] [Revised: 05/11/2020] [Accepted: 05/18/2020] [Indexed: 12/30/2022]
Abstract
Mechanisms explaining the link between psoriasis, a proinflammatory condition, and cardiovascular disease are not fully known. PCSK9 is predominantly expressed in hepatocytes as a critical regulator of lipid metabolism, and clinical trials targeting PCSK9 reduce cardiovascular disease. Independent of its role in lipid metabolism, PCSK9 levels associate with endothelial dysfunction and predict cardiovascular events. We used two separate human psoriasis cohorts and the K14-Rac1V12-/+ murine model of psoriasis to investigate PCSK9 and cardiovascular risk in psoriasis. In both psoriasis cohorts (n = 88 and n = 20), PCSK9 levels were 20% and 13% higher than in age-, sex-, and cholesterol-matched controls, respectively (P < 0.05 for each comparison) and correlated with PASI (r = 0.43, P < 0.05). Despite no difference in hepatocyte expression, K14-Rac1V12-/+ mice demonstrated skin-specific PCSK9 staining, which was confirmed in human psoriatic lesional skin. In patients with psoriasis, PCSK9 levels correlated with impaired endothelial vascular health (e.g., early atherosclerosis, β = 4.5, P < 0.01) and log converted coronary artery calcium score (β = 0.30, P = 0.01), which remained significant after adjustment for Framingham risk, body mass index, and active biologic use. Taken together, these findings suggest, independent of cholesterol, an association between circulating PCSK9 and early as well as advanced stages of atherosclerosis in psoriasis.
Collapse
Affiliation(s)
- Michael S Garshick
- Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA; Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA
| | - Yvonne Baumer
- Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Amit K Dey
- Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Ryan Grattan
- Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA
| | - Qimin Ng
- Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Heather L Teague
- Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Zu-Xi Yu
- Pathology Core Facility, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Marcus Y Chen
- Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Michael Tawil
- Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA
| | - Tessa J Barrett
- Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA
| | - James Underberg
- Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA
| | - Edward A Fisher
- Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA; Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA
| | - James Krueger
- Laboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA
| | - Tiffany M Powell-Wiley
- Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Martin P Playford
- Pathology Core Facility, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Jeffrey S Berger
- Center for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA; Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA; Division of Hematology, Department of Medicine, New York University School of Medicine, New York, New York, USA; Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York, New York, USA
| | - Nehal N Mehta
- Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
| |
Collapse
|
7
|
Kaufman H, Schurr K, Underberg J. A lost decade: No Meaningful Changes in LDL Cholesterol in the United States, 2008-2017: Insights from a National Reference Laboratory. J Clin Lipidol 2019. [DOI: 10.1016/j.jacl.2019.04.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Larrey D, Underberg J, Cannon CP, Makris L, Jurecka A, Blom D. Long-term Liver Safety of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Three-year Data from LOWER. ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.04.467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Underberg J, Harada-Shiba M, Hegele RA, McCullough PA, DiGioia K, Jurecka A, Stefanutti C, Blom D. LDL-C Therapeutic Target Attainment in Patients with Homozygous Familial Hypercholesterolemia treated with Lomitapide. ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.04.468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
10
|
Underberg J, Cannon CP, Larrey D, Makris L, Jurecka A, Blom D. Long-term Safety and Efficacy of Lomitapide in Patients with Homozygous Familial Hypercholesterolemia: Three-Year Data from LOWER. ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.04.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Vani A, Hurta V, Underberg J. Phenotypic Homozygous Familial Hypercholesterolemia and Elevated Lipoprotein (a). ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.04.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Gianos E, Schoenthaler A, Guo Y, Zhong J, Weintraub H, Schwartzbard A, Underberg J, Schloss M, Newman JD, Heffron S, Fisher EA, Berger JS. Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets (IMPACT) trial. Am Heart J 2018; 199:37-43. [PMID: 29754664 PMCID: PMC6276124 DOI: 10.1016/j.ahj.2017.12.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Accepted: 12/29/2017] [Indexed: 02/05/2023]
Abstract
BACKGROUND Patients undergoing cardiovascular (CV) procedures often have suboptimal CV risk factor control and may benefit from strategies targeting healthy lifestyle behaviors and education. Implementation of prevention strategies may be particularly effective at this point of heightened motivation. METHODS A prospective, randomized, pilot study was conducted in 400 patients undergoing a nonurgent CV procedure (cardiac catheterization ± revascularization) to evaluate the impact of different prevention strategies. Patients were randomized in a 1:1:1 fashion to usual care (UC; group A, n = 134), in-hospital CV prevention consult (PC; group B, n = 130), or PC plus behavioral intervention program (telephone-based motivational interviewing and optional tailored text messages) (group C, n = 133). The primary end point was the Δ change in non-high-density lipoprotein cholesterol (non-HDL-C) from baseline to 6 month. RESULTS The mean age was 64.6 ± 10.8 years, 23.7% were female, and 31.5% were nonwhite. After 6 months, the absolute difference in non-HDL-C for all participants was -19.8 mg/dL (95% CI -24.1 to -15.6, P < .001). There were no between-group differences in the primary end point for the combined PC groups (B and C) versus UC, with a Δ adjusted between group difference of -5.5 mg/dL (95% CI -13.1 to 2.1, P = .16). Patients in the PC groups were more likely to be on high-intensity statins at 6 months (52.9% vs 38.1%, P = .01). After excluding participants with baseline non-HDL-C <100 mg/dL (initial exclusion criterion), Δ non-HDL-C and Δ low-density lipoprotein cholesterol were improved in the PC groups compared to UC (non-HDL-C -8.13 mg/dL [-16.00 to -0.27], P = .04; low-density lipoprotein cholesterol -7.87mg/dL [-15.10 to -0.64], P = .03). CONCLUSIONS Although non-HDL-C reduction at 6 months following a nonurgent CV procedure was not significant in the overall cohort, an increased uptake in high-potency statins may translate into improved long-term health outcomes and cost reductions.
Collapse
Affiliation(s)
- Eugenia Gianos
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY.
| | - Antoinette Schoenthaler
- Department of Population Health, Center for Healthful Behavioral Change, New York University School of Medicine, New York, NY
| | - Yu Guo
- Department of Population Health, Center for Healthful Behavioral Change, New York University School of Medicine, New York, NY
| | - Judy Zhong
- Department of Population Health, Center for Healthful Behavioral Change, New York University School of Medicine, New York, NY
| | - Howard Weintraub
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY
| | - Arthur Schwartzbard
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY
| | - James Underberg
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY
| | - Michael Schloss
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY
| | - Jonathan D Newman
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY
| | - Sean Heffron
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY; Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY
| | - Edward A Fisher
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY; Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY
| | - Jeffrey S Berger
- Department of Medicine, Division of Cardiology, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York, NY; Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY
| |
Collapse
|
13
|
Larrey D, Underberg J, Cannon C, Makris L, Jurecka A, Blom D. Long-Term Liver Safety of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia: Three-Year Data from LOWER †. J Clin Lipidol 2018. [DOI: 10.1016/j.jacl.2018.03.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
14
|
Brown WV, Brown AS, Toth PP, Underberg J. What is sufficient drug therapy for lipoprotein elevations? J Clin Lipidol 2017; 11:1300-1308. [PMID: 29102497 DOI: 10.1016/j.jacl.2017.10.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
| | - Alan S Brown
- Advocate Health System, Loyola Stritch School of Medicine, Chicago, IL, USA
| | - Peter P Toth
- Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - James Underberg
- New York University Langone Medical School, New York, NY, USA
| |
Collapse
|
15
|
Weiss MC, Berger JS, Gianos E, Fisher E, Schwartzbard A, Underberg J, Weintraub H. Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. J Clin Lipidol 2017; 11:1177-1180. [DOI: 10.1016/j.jacl.2017.07.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Revised: 07/02/2017] [Accepted: 07/17/2017] [Indexed: 10/19/2022]
|
16
|
Weiss M, Gianos E, Underberg J, Berger J, Weintraub H. Lipoprotein(a) As A Clinical Decision-Aid Tool*. J Clin Lipidol 2016. [DOI: 10.1016/j.jacl.2016.03.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
17
|
Underberg J, Larrey D, Makris L, Schwamlein C, Phillips H, Bloedon L, Blom D. Lomitapide Observational Worldwide Evaluation Registry (LOWER): One-Year Data†. J Clin Lipidol 2016. [DOI: 10.1016/j.jacl.2016.03.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
18
|
Blom DJ, Fayad ZA, Kastelein JJ, Larrey D, Makris L, Schwamlein C, Bloeden L, Underberg J. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. J Clin Lipidol 2016; 10:273-82. [DOI: 10.1016/j.jacl.2015.11.011] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 09/09/2015] [Accepted: 11/22/2015] [Indexed: 12/11/2022]
|
19
|
Rudy H, Levy A, Vani A, Balakrishnan R, Guo Y, Newman J, Wentraub H, Schwartzbard A, Fisher E, Underberg J, Berger J, Gianos E. Racial and Ethnic Disparity in Cardiovascular Risk Factor Control in Patients Presenting for Elective Catheterization*. J Clin Lipidol 2015. [DOI: 10.1016/j.jacl.2015.03.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
O’Brien EC, DeGoma E, Moriarty P, Linton MF, Shapiro M, Duell B, Ballantyne C, Neal W, Ahmad Z, Duffy D, Hudgins L, Hemphill L, Underberg J, Watson K, Gidding S, Baum S, Dilzell K, Ross J, Pickhardt D, Kindt I, Rader D, Wilemon K, Roe M, Knowles J. INITIAL RESULTS FROM THE CASCADE-FH REGISTRY: CASCADE SCREENING FOR AWARENESS AND DETECTION OF FAMILIAL HYPERCHOLESTEROLEMIA. J Am Coll Cardiol 2015. [DOI: 10.1016/s0735-1097(15)61372-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
21
|
Pourfarzib R, Morris P, McLain K, Malave H, Underberg J, Le NA, Shapiro M, Winegar D. Relationship between plasma apolipoprotein B concentrations and LDL particle number. RRCC 2014. [DOI: 10.2147/rrcc.s65976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
22
|
Tully L, Gianos E, Vani A, Guo Y, Balakrishnan R, Schwartzbard A, Slater J, Stein R, Underberg J, Weintraub H, Fisher E, Berger JS. Suboptimal risk factor control in patients undergoing elective coronary or peripheral percutaneous intervention. Am Heart J 2014; 168:310-316.e3. [PMID: 25173542 DOI: 10.1016/j.ahj.2014.05.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2014] [Accepted: 05/14/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND The American Heart Association recommends targeting 7 cardiovascular (CV) health metrics to reduce morbidity and mortality. Control of these targets in patients undergoing CV intervention is uncertain. METHODS We prospectively studied patients undergoing elective percutaneous coronary or peripheral intervention from November 2010 to May 2012. We recorded data on patient demographics, clinical characteristics, and social history. Risk factor control was categorized as ideal, intermediate, or poor according to the 7 American Heart Association-defined CV health metrics (smoking status, body mass index, physical activity, diet, cholesterol, blood pressure, and metabolic control). Linear regression model was used to evaluate the association between baseline characteristics and poor CV health. RESULTS Among 830 consecutive patients enrolled, mean age is 67.3 ± 10.8 years, 74.2% are male, and 62.1% are white. The adequacy of achievement of ideal CV health is suboptimal in our cohort; the mean number of ideal CV metrics is 2.15 ± 1.06. Less than 1 in 10 (9.7%) met ≥4 ideal CV health metrics. After multivariate analysis, male sex (P = .04), nonwhite race (P = .01), prior coronary artery disease (P < .01), prior peripheral arterial disease (P < .01), and history of depression (P = .01) were significantly associated with poor CV health. CONCLUSIONS Among patients referred for elective CV intervention, achievement of ideal CV health is poor. Elective interventions represent an opportunity to identify and target CV health for risk factor control and secondary prevention.
Collapse
|
23
|
Greet B, Milne V, Singh A, Fisher E, Underberg J. Impact of Superstorm Sandy on the Lipid Panel of a Patient with Familial Hypercholesterolemia*. J Clin Lipidol 2013. [DOI: 10.1016/j.jacl.2013.03.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Underberg J, Pokrywka G, Garner H, Pourfarzib R, Winegar D. Heterogeneity of LDL and HDL Particle Concentrations in Subjects Meeting LDL-Cholesterol Goals. J Clin Lipidol 2013. [DOI: 10.1016/j.jacl.2013.03.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Singh A, Milne V, Underberg J. Rise in Serum Lipids After Dietary Incorporation of Coconut Fats*. J Clin Lipidol 2013. [DOI: 10.1016/j.jacl.2013.03.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Chiu KM, Dayspring T, Underberg J. Oral Contraceptives: A Cause of Elevated LDL-Particle Number in Two Young Dyslipidemic Women*. J Clin Lipidol 2013. [DOI: 10.1016/j.jacl.2013.03.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Singh A, Milne V, Cuchel M, Fisher E, Underberg J, Hegele R. Severe Hypertriglyceridemia and Recurrent Pancreatitis In a Patient With SLE and an Underlying Mutation in the Lipase Maturation Factor-1 Gene*. J Clin Lipidol 2013. [DOI: 10.1016/j.jacl.2013.03.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
28
|
Balakrishnan R, Berger J, Vani A, Cioce L, Burdowski J, Kampaktsis P, Fisher E, Schloss M, Schwartzbard A, Weintraub H, Underberg J, Slater J, Gianos E. Prevalence of Unrecognized Diabetes, Prediabetes and Metabolic Syndrome in Patients Referred for Non-Urgent Percutaneous Intervention*. J Clin Lipidol 2013. [DOI: 10.1016/j.jacl.2013.03.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
Singh A, Heffron S, Zagzag J, Youn H, Fielding G, Ren-Fielding C, Underberg J. ARE THE IMPROVEMENTS IN LIPID PARAMETERS AFTER GASTRIC BANDING DURABLE IN THE LONG-TERM: FIVE YEARS OF FOLLOW-UP. J Am Coll Cardiol 2013. [DOI: 10.1016/s0735-1097(13)61426-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Morris P, Bhalla N, Mclain K, Malave H, Underberg J, Teague RJ, Garner H, Winegar D, Pourfarzib R. DISCORDANCE IN LOW-DENSITY LIPOPROTEIN PARTICLE NUMBER (LDL-P) AND APOLIPOPROTEIN B (APO B) LEVEL. J Am Coll Cardiol 2013. [DOI: 10.1016/s0735-1097(13)61360-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Heffron S, Singh A, Zagzag J, Youn HA, Underberg J, Fielding GA, Ren CJ. GASTRIC BANDING RESOL/ES METABOLIC SYNDROME IN OBESE SUBJECTS OVER FIVE YEARS OF FOLLOW-UP. J Am Coll Cardiol 2013. [DOI: 10.1016/s0735-1097(13)61342-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
32
|
Tully L, Gianos E, Vani A, Guo Y, Balakrishnan R, Ullah O, Schloss M, Schwartzbard A, Slater J, Stein R, Underberg J, Weintraub H, Fisher E, Berger J. SUBOPTIMAL RISK FACTOR CONTROL IN PATIENTS UNDERGOING ELECTIVE CARDIOVASCULAR INTERVENTION. J Am Coll Cardiol 2013. [DOI: 10.1016/s0735-1097(13)61457-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Gianos E, Gonzalez-Santos L, Vani A, Cioce L, Schloss M, Schwartzbard A, Weintraub H, Underberg J, Fisher E, Berger J. Attainment of Risk Factor Modification Goals in Patients Undergoing Percutaneous Cardiovascular Interventions∗. J Clin Lipidol 2012. [DOI: 10.1016/j.jacl.2012.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Gonzalez Santos LE, Underberg J. Electronic Chart Review of A Multispecialty Internal Medicine Practice Evaluating Appropriate Identification of Patients with Familial Hyperlipidemia*. J Clin Lipidol 2011. [DOI: 10.1016/j.jacl.2011.03.058] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|